VIROTHERAPY RESEARCH IN GERMANY - FROM ENGINEERING TO TRANSLATION A Review as contribution to the Combined Annual Meeting of the German and European Societies of Gene (and Cell) Therapy 2017.
Fiche publication
Date publication
septembre 2017
Journal
Human gene therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARCHINI Antonio
Tous les auteurs :
Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM
Lien Pubmed
Résumé
Virotherapy is a unique modality for treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Different viruses are being developed as OVs preclinically and clinically, several of them engineered to encode therapeutic proteins for tumor-targeted gene therapy. Scientists and clinicians in Germany have made significant contributions to OV research and development, which are highlighted in this review article. Innovative strategies for "shielding", entry- or post-entry targeting, and "arming" of OVs have been established focusing on adeno-, measles, parvo-, and vaccinia virus platforms. Thereby, new generation virotherapeutics have been derived. Moreover, immunotherapeutic properties of OVs and combination therapies with pharmaco-, radio- and especially immunotherapy have been investigated and optimized. German investigators are increasingly assessing their OV innovations in investigator-initiated and sponsored clinical trials. As prototype, parvovirus has been tested as OV from preclinical proof-of-concept up to first-in-man clinical studies. The approval of the first OV in the western world, T-VEC (Imlygic TM), has further spurred involvement of investigators in Germany in international multicenter studies. With the recent encouraging developments in funding, commercialization and regulatory procedures, more German engineering will be translated into OV clinical trials in the near future.
Mots clés
Animals, Clinical Trials as Topic, Combined Modality Therapy, Drug Evaluation, Preclinical, Genetic Therapy, methods, Genetic Vectors, genetics, Germany, Humans, Models, Animal, Oncolytic Virotherapy, methods, Oncolytic Viruses, genetics, Research, Treatment Outcome
Référence
Hum. Gene Ther.. 2017 Sep;: